Welcome to our dedicated page for Xenon Pharmaceuticals news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceuticals stock.
Xenon Pharmaceuticals Inc. reports news on its neuroscience-focused biopharmaceutical pipeline, including drug discovery, clinical development and commercialization plans for neurological and psychiatric disorders. The company’s lead molecule, azetukalner, is a KV7 potassium channel opener in Phase 3 clinical development for epilepsy, major depressive disorder and bipolar depression.
Recurring updates include azetukalner clinical data in focal onset seizures, presentations at medical and investor conferences, financial results, business updates, public offerings, inducement equity grants and early-stage potassium and sodium channel programs, including KV7 and NaV1.7 candidates being developed for pain.
Xenon Pharmaceuticals (Nasdaq: XENE) will report Q1 2026 financial results and provide a business update after U.S. markets close on May 7, 2026 at 4:30pm ET.
A live webcast will be available via the company website; dial-in details and conference ID 7898598 are provided for callers. Xenon’s lead molecule, azetukalner, is in Phase 3 for epilepsy, major depressive disorder, and bipolar depression. The company also has Phase 1 KV7 and NaV1.7 programs targeting pain and maintains offices in Vancouver and Boston.
Xenon (NASDAQ: XENE) presented Phase 3 X-TOLE2 and 48-month X-TOLE OLE data for azetukalner in focal onset seizures at AAN 2026. In X-TOLE2, azetukalner 25 mg produced a -53.2% median percent change in monthly seizures versus -10.4% for placebo (p<0.0001).
In the ≥48-month OLE, month 48 MPC reached -90.9% and 38.2% of participants achieved ≥12 months seizure freedom; Xenon expects to submit an FDA NDA in Q3 2026.
Xenon Pharmaceuticals (Nasdaq: XENE) will present at four investor conferences in Q2 2026: Bloom Burton (Apr 22), Bank of America (May 14), RBC (May 19) and Jeffries (Jun 4).
Webcast details and replay availability will be posted on the company Investors section; dates and times are subject to change.
Xenon (Nasdaq: XENE) will present five abstracts at the AAN Annual Meeting April 18-22, 2026, including a Late-breaking Science oral and poster of topline Phase 3 X-TOLE2 results for azetukalner in focal onset seizures and a ≥48-month interim analysis from the X-TOLE open-label extension.
Additional presentations cover real-world titration burden, comorbidity impacts, and preclinical NaV1.1 Dravet data; Xenon will staff Booth #2330 in the exhibit hall.
Xenon Pharmaceuticals (Nasdaq: XENE) closed an upsized underwritten public offering on March 12, 2026, raising approximately $747.5 million in gross proceeds.
The company sold 12,236,843 common shares (including 1,710,526 shares from full exercise of the underwriters' option) and issued pre-funded warrants to purchase up to 877,194 common shares at $56.9999 each; each pre-funded warrant has an exercise price of $0.0001.
Xenon Pharmaceuticals (Nasdaq: XENE) priced an upsized underwritten public offering totaling 10,526,317 common shares and pre-funded warrants for 877,194 shares at $57.00 per common share (pre-funded warrants $56.9999), raising approximately $650.0 million in gross proceeds.
The offering includes a 30-day underwriter option to buy up to 1,710,526 additional common shares and is expected to close on or about March 12, 2026. The securities were registered on a shelf registration filed August 9, 2024. No sales are being made in Canada.
Xenon Pharmaceuticals (Nasdaq: XENE) announced a proposed underwritten public offering of $500.0 million of common shares, with underwriters having a 30-day option to purchase up to an additional $75.0 million. All shares are being offered by Xenon and the offering is subject to market and other conditions.
Joint book-running managers include J.P. Morgan, Jefferies, TD Cowen, Stifel, RBC Capital Markets, and William Blair; an effective shelf registration was filed on August 9, 2024. The offering will be made only by prospectus and prospectus supplement.
Xenon (Nasdaq: XENE) reported positive topline Phase 3 X-TOLE2 results for azetukalner in focal onset seizures (FOS) on March 9, 2026. The trial met its primary endpoint with a -53.2% median percent change (MPC) in monthly FOS frequency for 25 mg versus -10.4% for placebo (placebo-adjusted -42.7%, p=6e-12).
Key secondary RR50 was 54.8% (25 mg) versus 20.8% placebo. Safety was consistent with prior studies. Xenon plans to file an NDA in Q3 2026 and will present X-TOLE2 as a Late Breaking Science oral at AAN on April 19, 2026.
Xenon Pharmaceuticals (Nasdaq: XENE) will announce topline results from the Phase 3 X-TOLE2 study of azetukalner in focal onset seizures on Monday, March 9, 2026. A live webcast and replay will be available via the company's Investors website; conference call details are provided.
Conference call: 8:00 am ET (5:00 am PT) on March 9, 2026; dial-in and webcast registration information available.
Xenon Pharmaceuticals (Nasdaq: XENE) reported Q4 and full-year 2025 results and a business update highlighting imminent clinical and cash milestones. X-TOLE2 Phase 3 topline data in focal onset seizures are expected in the first half of March 2026, with an anticipated NDA submission in H2 2026. Pro forma cash of $716.0M (including Q1 2026 ATM proceeds) supports operations into the second half of 2027. Multiple Phase 3 azetukalner studies continue to enroll; X-NOVA2 MDD topline data expected H1 2027. Early-stage Phase 1 data for XEN1701 and XEN1120 expected in 2026.